Published in final edited form as:

Cancer Immunol Immunother. 2013 July ; 62(7): . doi:10.1007/s00262-013-1435-5.

Activation, Dysfunction and Retention of T Cells in Vaccine Sites after Injection of Incomplete Freund's Adjuvant, With or Without Peptide

Elise P. Salerno^{1,*}, Sofia M. Shea^{2,*}, Walter C. Olson¹, Gina R. Petroni³, Mark E. Smolkin³, Chantel McSkimming⁴, Kimberly A. Chianese-Bullock¹, and Craig L. Slingluff Jr.¹

¹Division of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, VA USA

²Department of Pathology, University of Virginia, Charlottesville, VA USA

³Department of Public Health Sciences, University of Virginia, Charlottesville, VA USA

⁴Cardiovascular Research Center, University of Virginia, Charlottesville, VA USA

Abstract

We conducted a randomized clinical trial in 45 patients with resected AJCC stage IIB-IV melanoma to characterize cellular and molecular events at sites of immunization with incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA. At a primary vaccine site, all patients received a multi-peptide melanoma vaccine in IFA. At a replicate vaccine site, which was biopsied, group 1 received IFA only; group 2 received vaccine in IFA. Lymphocytes isolated from replicate vaccine site microenvironments (VSME) were compared to time-matched peripheral blood mononuclear cells (PBMC) in ELISpot and flow cytometry assays. Compared to PBMC, the VSME had fewer naïve and greater proportions of effector memory CD8⁺ T cells (T_{CD8}). The vast majority of T_{CD8} within the VSME were activated (CD69⁺), with a concentration of antigen-specific (tetramer^{POS}) cells in the VSME, particularly in vaccine sites with peptide (group 2). CXCR3⁺ lymphocytes were concentrated in the VSME of all patients, suggesting IFA-induced chemokine recruitment. T_{CD8} expression of retention integrins E 7 and 1 1 was elevated in VSME, with the highest levels observed in antigen-specific cells in VSME containing peptide (group 2). T_{CD8} retained in the VSME of both groups were strikingly dysfunctional, with minimal IFN- γ production in response to peptide stimulation and few tetramer^{POS} cells producing IFN- γ . These data suggest that vaccine-induced selective retention and dysfunction of antigen-specific T_{CD8} within VSME may represent a significant mechanism underlying transient immune responses and low clinical response rates to peptide vaccines administered in IFA.

Keywords

Human; T cell; Incomplete Freund's adjuvant; peptide vaccine; melanoma; CIMT 2012

Corresponding Author: Craig L. Slingluff, Jr., M.D., Address: UVA Health System, Carter Harrison Research Building, G713, P.O. Box 800709, Charlottesville, VA, 22908-0709, USA, Phone: 434-924-1730, Fax: 434-243-6844, cls8h@virginia.edu.

*Equal Contribution

Conflict of Interest: The authors declare that they have no conflict of interest.

Introduction

Clinical activity of cancer vaccines is now supported by approval of sipuleucel-T (Provenge) for prostate cancer, and improved clinical outcome of advanced melanoma by adding a melanoma peptide vaccine to high-dose IL-2 [1]. However, melanoma vaccines alone have induced objective clinical regressions in only 3–6% of patients [2], despite inducing circulating anti-tumor T cells in 70–100% of patients [3,4]. Unfortunately, the immune responses are often of low magnitude and duration [3], which likely limits their clinical activity and may explain in part the low clinical response rates.

A vaccine adjuvant is necessary to activate dendritic cells (DCs) and to induce a favorable immunologic milieu; however, little is known about the cellular and molecular events induced by such adjuvants. A widely used adjuvant is incomplete Freund's adjuvant (IFA), which was developed in the 1930s to induce antibody responses to viral proteins [5]. It is not clear what adjuvants are best to induce durable T cell responses to defined cancer antigens. We have previously reported a histologic analysis of sites of immunization with peptides in an emulsion with Montanide ISA-51 (an IFA), using immunohistochemistry, which suggested that the vaccine site microenvironment (VSME) is not optimized for induction of strong Th1/Tc1 responses, with induction, instead, of FoxP3⁺ cells and of eosinophils, suggestive of a Th2 dominant microenvironment [6].

Immunization in IFA creates a depot of antigen plus adjuvant and can lead to chronic inflammation in the VSME that is clinically prominent, and may persist for years. Chronic inflammation can induce lymphoid neogenesis and development of tertiary lymphoid organs (TLO) [7–9]. This can occur at sites of cancer vaccines, where lymphoid aggregates contain separate B and T cell areas, mature dendritic cells, high endothelial venule (HEV)-like vessels and lymphoid cytokines [10]. Thus, vaccines containing IFA may induce a VSME that supports antigen presentation in the vaccine site itself [10]; however, lymphoid aggregates in the VSME may lack full function of a lymph node. Other data raise questions about whether the chronic depot of IFA-containing vaccines may have negative effects on persistent systemic immunity and tumor control: in murine models, activated, antigen specific T cells traffic selectively to such vaccine sites rather than to tumor, and may die there [11]. These findings remain to be confirmed in humans. To address whether the VSME induced by peptide vaccines in IFA may recruit and/or retain antigen-specific T cells in humans, we have evaluated the phenotype and function of antigen-specific CD8⁺T cells from vaccine sites and PBMC. We present data that the VSME contains antigen-reactive effector memory T cells that are either exhausted or in a prolonged refractory state, and that are retained in the VSME, with high expression of retention integrins (α 11 and E7).

Materials and Methods

Patient selection

Specimens for this study were obtained in a clinical trial of a multi-peptide vaccine for melanoma: NCT00705640, University of Virginia (Mel48). Patients with resected AJCC stage IIB–IV arising from cutaneous, mucosal, ocular, or unknown primary site were eligible. Inclusion criteria included: expression of HLA-A1, A2, A3, or A11; age of 18 years or greater; ECOG performance status 0–1; adequate blood counts, liver, and renal function; negative serologies for HIV and Hepatitis C; and ability to give informed consent. Exclusion criteria included: multiple brain metastases; cytotoxic chemotherapy, interferon therapy, or radiation within the preceding 4 weeks; known or suspected allergies to any vaccine component; pregnancy; body weight less than 110 lbs; use of steroids; or Class III–IV heart disease. Patients were studied following informed consent, with Institutional Review Board (IRB/HSR #13498) and FDA approval (BB-IND #12191).

Patient assignment and study protocol

Patients were randomized to one of two groups, and one of five arms within each group. All received the full vaccine (12 Class I MHC restricted melanoma peptides and a tetanus helper peptide emulsified in IFA) at the primary vaccine site (days 1, 8, 15, 29, 36, and 43), plus a 2nd vaccine at a replicate vaccine site, where the injectate differed between the two study groups: IFA only (group 1) or full vaccine (group 2). Within each study group, there were five arms: with excisional biopsy of the replicate site: pre-vaccination (week 0, Arm A), 1 week after the first vaccine (week 1, Arm B), 1 week after the third vaccination (week 3, arm C), 1 week after the sixth vaccination (week 7, arm D), or 6 weeks after the sixth vaccination (week 12, arm E).

Vaccine preparation and dosage

The full vaccine consisted of 12 class I MHC-restricted melanoma peptides (12-MP vaccine - Supplemental Table S1; 50 µg each peptide) and a tetanus helper peptide (Peptide-tet; 100 µg) in 0.5 mL aqueous solution, emulsified 1:1 with 0.5 mL Montanide ISA-51. The total injected volume was 1.0 mL, one half given subcutaneously (s.c), the other half intradermally (i.d.), through a single skin puncture. The replicate vaccine containing only adjuvant was an emulsion of saline (0.5 mL) plus 0.5 mL Montanide ISA-51, also administered s.c. and i.d.

Design and sample size

This was a pilot study to obtain preliminary measures of several pre-specified endpoints of interest. For sample size determination, we characterized power in terms of effect, with planned use of regression models maximizing power for small sample size. Four patients were to be accrued to each biopsy time point for each treatment group. Maximum accrual to the study was estimated to be 44 subjects in order to accrue the target 36 eligible subjects required to meet the study objectives, plus a 5% ineligibility rate and over-accrual of subjects scheduled to have biopsies at the later time points. Total accrual was 45.

ELISpot

ELISpot assays for interferon gamma (IFN- γ) were performed on PBMCs and on lymphocytes from the VSME (Fig. 1). Assays were performed directly *ex vivo* after cryopreservation (direct ELISpot), as previously reported [12]. Criteria for positive immunologic response were: magnitude of response two-fold pre-vaccination value and experimental negative control, an increase of at least 0.02% of CD8⁺ T cells over negative control, and no overlap between the 1SD intervals of the response and negative controls [12]. Calculated interassay coefficients of variation for normal donor PBMC for high and low responders to CEF peptides were 18% and 23%, respectively.

Immunostaining and multi-parametric flow cytometry

Single-cell suspensions of cryopreserved PBMC and mononuclear cell specimens isolated from vaccine site biopsies using methods previously described [12] were thawed in warm RPMI-1640 (Life Technologies: Grand Island, NY) medium containing 5% fetal bovine serum (FBS; Sigma-Aldrich: St. Louis, MO), and 100,000 units/ml deoxyribonuclease I (Cat. # LS00219; Worthington Biochemical Co.: Lakewood, NJ). Cells were washed in phosphate buffer solution (PBS) and were labeled with the LIVE/DEAD® Fixable Aqua dead cell stain (Life Technologies) for viability according to manufacturer's instructions. Aliquots of Aqua-labeled cells were added to wells containing mixtures of Class I MHC-peptide multimers (Beckman Coulter; Indianapolis, IN) relevant to the patient's HLA type for a total volume of 25 µL, as described [13]. Also, a pentamer (Proimmune; Oxford, UK) for SLFRAVITK (MAGE-A1₉₆₋₁₀₄) was incorporated in the HLA-A3 pool of tetramers.

After incubation at 4°C for 20 minutes, 25 µL labeled antibody mixtures for integrins, homing receptors, chemokine receptors, and activation/maturation markers were added to the cell suspensions (details in Supplemental Table S2). then incubated an additional 20 minutes at 4°C, washed twice in FACS buffer (PBS + 2% FBS), then fixed in 2% paraformaldehyde (Sigma-Aldrich) in PBS for 10 minutes at room temperature, and washed once. Immunostained cells were held overnight at 4°C then acquired on a CyAn ADP LX 9 color flow cytometer (Beckman Coulter) equipped with 3 lasers. Flow cytometry data were analyzed with FlowJo version 8.8.6 (Tree Star; Ashland, OR), gated on viable, single cell populations.

***In vitro* stimulation of vaccine site cell suspensions**

Cells were thawed, counted, and incubated with a pool of the 12 melanoma peptides (40 µg/ml each) for 2 hours, washed and cultured with IL2 (20 IU/mL) in culture medium (RPMI1640 + 10% human AB serum). Cultures were fed with culture media with IL-2 as needed. No media replacement was necessary. On day 14, cells were collected and viable cell recovery determined.

Intracellular cytokine stimulation and staining

Cells were stimulated with peptide-pulsed C1R-A2 cells (T:APC ratio 2:1) or with PMA +ionomycin (50 ng/mL and 1 µM, respectively). Cells were incubated 4 hours in AIM V + 5% HuAB serum in the presence of GolgiPlug (BDBiosciences; San Jose, CA), then washed in PBS and labeled with Aqua 30 min at 4°C. Pooled tetramers, or the irrelevant tetramer were added and incubated 45 minutes at 4°C. Cells were washed and fixative (BioLegend; San Diego, CA) added for 20 minutes at room temperature. Cells were washed twice and left overnight at 4°C, then permeabilized, to which was added a mixture of antibodies in permeabilization buffer (BDBiosciences) consisting of anti-CD8-FITC (Beckman Coulter), CD3 Pacific Blue, CD4-PE-Texas red, CD19 PE-Texas red (Invitrogen; Grand Island, NY), and interferon-gamma-APC (eBioscience; San Diego, CA). Cells were incubated 60 minutes at 4°C, then washed 3 times in permeabilization buffer and twice in PBS+0.1% BSA+0.1% sodium azide. Cells were acquired on a Beckman Coulter CyAn ADP LX 9 Color flow cytometer and analyzed using FlowJo software.

Statistical analysis

For each assay, data from all patients with available samples from the vaccine site and time-matched PBMC were evaluated using SPSS 20 (IBM: Armonk, NY). Linear regression models were used to assess the difference between vaccine site values and time-matched PBMC, accounting for two variables: Patient group and Study Arm (biopsy time point). To minimize the impact of outliers in this small patient population and to satisfy model assumptions, square root transformation of endpoints was employed for all analyses. In analyses of tetramer^{pos} and tetramer^{neg} subsets of cells, samples containing fewer than 5 tetramer^{pos} cells were excluded, which resulted in the elimination of 1 group 2C patient from CCR7/CD45RA, CXCR3, CLA and CD62L analyses. In this pilot study, no adjustments were made for multiple comparisons. All tests were two-sided and considered significant for p 0.05. All results are reported after adjusting for patient group and study arm (time of biopsy).

Results

Patients Studied

Forty-five patients with resected AJCC stage IIB–IV melanoma were enrolled in a clinical trial of a multi-peptide vaccine (Mel 48, Fig. 1), from which histologic findings have been

reported [6]. All were vaccinated with 12MP plus tetanus helper peptide in a primary vaccine site. Each had “replicate vaccine” injection at a second site, which was biopsied. The replicate vaccine consisted of either IFA alone (group 1), or IFA with peptides (group 2). Patients enrolled in the two study arms were similar (Table 1). Replicate site biopsies were obtained in 38 patients (84%). Vaccine site biopsies from study arms A (week 0), B (week 1), and E (week 12) contained insufficient lymphocytic infiltrates for both ELISpot and flow cytometric evaluation. Data from both VSME and time matched PBMC were obtained from 13 patients from vaccine site biopsies at weeks 3 and 7: 2, 3, 5, and 3 in groups 1C, 1D, 2C, and 2D, respectively.

Composition of cells in the VSME

CD8⁺ T cells were characterized based on CCR7 and CD45RA expression [14]. Compared to PBMC, the VSME had fewer naïve cells (T_{naïve}, CD45RA⁺/CCR7⁺) and greater proportions of effector memory cells (T_{EM}, CD45RA^{neg}/CCR7^{neg}, Figure 2). Among tetramer^{neg} cells, T_{naïve} were lower in VSME than PBMC (p=0.003) and T_{EM} were higher (P<0.001, Fig. 2a,c). Among tetramer^{pos} cells, T_{EM} were more prevalent in the VSME than in PBMC (p=0.033, Fig 2d). Proportions of central memory T cells (T_{CM}, CD45RA^{neg}/CCR7⁺) were very low for all samples, were slightly higher in the VSME than PBMC overall (p=0.004), but not among tetramer^{pos} cells (Supplemental Fig. SF1). There were no significant differences in CD45RA^{pos} effector memory (T_{EMRA}, CD45RA^{pos}/CCR7^{neg}) proportions between sites (Supplemental Fig. SF1).

Activation and antigen specificity in the vaccine site

Among all subjects, CD69⁺ CD8⁺ T cells were enriched in the VSME compared to PBMC (p<0.001, Fig. 3b). The proportion of tetramer^{pos} cells in VSME trended higher than in PBMC overall but did not reach statistical significance (Fig. 3d); review of graphical data prompted examination of group 2 alone: among those patients with antigen in the biopsied VSME, there were more tetramer^{pos} CD8⁺ T cells than in PBMC (p=0.003 Fig. 3d). CD4⁺ T cell responses to the tetanus helper peptide were not a focus of this report and were not evaluable with multimers. Results of direct IFN- ELISpot assay for response to tetanus helper peptide are provided in Supplemental Table S4.

Dysfunction of antigen-specific cells

Antigen-specific CD8⁺ T cells in the VSME appeared to be dysfunctional for all patients, regardless of the presence or absence of peptides at the VSME. Despite increased tetramer^{pos} cells in the VSME, there were fewer ELISpot⁺ cells per 10⁵ CD8⁺ T cells in the VSME than in PBMC (p=0.033, Supplemental Fig. SF2). Vaccine sites contained fewer functional cells per tetramer^{pos} T cells than PBMC (p=0.053, Fig. 3e).

To evaluate preliminarily whether the apparent dysfunction of tetramer^{pos} cells in the VSME was reversible, a stimulated ELISpot assay was performed. Cryopreserved cell suspensions from 5 vaccine site biopsies were stimulated with the 12MP *in vitro* and placed in a 14 day culture with IL-2, using methods previously reported [4]. Lymphocytes expanded very poorly in all samples; only 2 yielded adequate cell numbers for flow cytometry (viable cells only 3% and 15% of the input cell number), which revealed no expansion of tetramer^{pos} cells after stimulation (data not shown).

Expression of homing molecules

The VSME overall contained greater proportions of T cells expressing the chemokine receptor CXCR3 than PBMC (Fig. 4a,b). This was true among CD4⁺ T cells (p<0.001, Fig. 4c), tetramer^{neg} and tetramer^{pos} CD8⁺ T cells (p=0.001, p<0.001, respectively, Fig. 4a, b).

Cutaneous leukocyte antigen (CLA) was inconsistently elevated in the VSME. Among tetramer^{neg} CD8⁺ T cells, CLA⁺ cells were increased in the VSME ($p=0.004$, Supplemental Fig. SF3a), but no evident enhancement of CLA was observed among tetramer^{pos} CD8⁺ T cells in the VSME (Supplemental Fig. SF3b).

CD62L (L-selectin), a high endothelial venule homing molecule, was present on PBMC, but CD62L⁺ CD8⁺ T cells were notably decreased or absent in all VSME, for both tetramer^{neg} and tetramer^{pos} subsets of VSME CD8⁺ T cells ($p=0.004$, $p<0.001$, respectively; Supplemental Fig. SF3c, d).

Increased expression of retention integrins

Expression of retention integrins E 7 and 1 1 was elevated in the VSME, particularly in group 2 (Fig. 5). Among tetramer^{neg} CD8⁺ T cells E 7 expression was higher in the VSME than in PBMC ($p<0.001$, Fig. 5a). Among tetramer^{pos} CD8⁺ T cells in the vaccine site, E 7 expression was not significantly increased in this small sample of patients; however, graphical depiction of the data showed that the greatest E 7 expression was among tetramer positive cells in group 2 (Fig. 5b): average percentages of cells expressing E 7 in VSME and PBMC were 30% and 16%, respectively, at week 3 and 50% and 10%, respectively, at week 7 (Fig. 5b). In all patients, E 7 was nearly absent from tetramer^{neg} cells in PBMC at every time point.

The proportion of CD8⁺ T cells expressing 1 1 was higher in the VSME than PBMC, for both tetramer^{neg} ($p<0.001$, Fig. 5c) and tetramer^{pos} CD8⁺ T cells ($p=0.001$, Fig. 5d). Group 2 VSME had highly elevated 1 1 expression among tetramer^{pos} cells, with means of 74% expressing it at week 3 (Fig. 5d) and 78% at week 7. In matched PBMC, 1 1⁺ proportions of tetramer^{pos} CD8⁺ T cells averaged 24% at week 3 and 30% at week 7. In all patients, 5% or less of tetramer^{neg} cells in PBMC were 1 1⁺ at any time point.

Differences between study groups and time points

For most measures evaluated, there were no statistically significant differences between patients in Groups 1 and 2. However, expression of retention integrins was higher in group 2 VSME samples (IFA and peptides) than in group 1 (IFA alone), among tetramer^{neg} CD8⁺ T cells, for E 7 ($p=0.008$) and for 1 1 ($p=0.015$). Elevated VSME expression of 1 1 among tetramer^{pos} CD8⁺ T cell trended toward a greater effect in group 2 ($p=0.120$).

Similarly, the effect size of the difference between VSME and PBMC did not differ significantly from week 3 to week 7 for most measures, except that greater numbers of ELISpot⁺ T cells were observed in the VSME week 7 than week 3 ($p=0.017$). Comparing ELISpot⁺ to tetramer^{pos} ratios, a smaller proportion of functional cells was observed in the vaccine site at week 3 than at week 7 ($p=0.059$).

Discussion

We have previously reported features of lymphoid neogenesis in the VSME after IFA-based vaccines [10]. However, it is not clear if the resulting lymphoid aggregates are fully functional tertiary lymphoid organs (TLO). The findings of the present study suggest that they are not fully functional. TLO are characterized by high endothelial venules expressing peripheral node addressin [PNAd, which binds CD62L (L-selectin) on lymphocytes] and also by high levels of CCL19 and CCL21, ligands for CCR7. In the VSME lymphoid aggregates, we might anticipate an enrichment of T cell populations expressing CCR7 and CD62L, including naïve T cells and T_{CM}. Instead, we find that in all patients, including those receiving only IFA at the vaccine site biopsied, the VSME CD8⁺ T cells are dominated by a large population of T_{EM} phenotype with moderate proportions of T_{EMRA}

and scant T_{naive} and T_{cm} (Fig. 2, Supplemental Fig. SF1). Similarly, cells bearing CD62L are significantly reduced or absent in the VSME (Supplemental Fig. SF3).

Low numbers of T_{naive} in the vaccine site may reflect a return of T_{naive} to circulation after encountering the VSME or *in situ* conversion to a memory phenotype in the VSME after exposure to antigen. Despite loss of CCR7, T_{EM} cells typically display other chemokine receptors and adhesion molecules required for homing to inflamed tissues; thus, T_{EM} in the vaccine site may also be recruited from circulation and retained. The dominance of memory cells in the VSME of group 2 is counterintuitive, as peptide antigens administered in IFA emulsion might be expected to activate memory cells and to convert them to effectors. However, most T cells in the VSME are not immediately adjacent to vaccine emulsion depot, which resides in the tissue as small, loculated islands evident in histologic sections [10]. Also, the half-lives of peptides in our vaccine are short [15]; they may be degraded before encounter dermal perivascular lymphocytes. Whether from conversion or lack of retention, the marked absence of T_{naive} in the VSME lymphoid aggregates suggests that these sites are not fully functional TLO, since higher proportions of naïve cells are found in normal nodes.

In a murine model of vaccination for melanoma, activated, antigen-specific T cells traffic to vaccine sites containing IFA plus peptide, and the vaccine site acts as a sink or graveyard for these tumor-specific T cells [11]. Several findings from the present study corroborate, in humans, what has been observed in the murine model: the VSME manifests a marked, long-lasting accumulation of activated ($CD69^+$) $CD8^+$ T cells, with concentration of antigen-specific (tetramer^{pos}) cells in the VSME in group 2 patients, in whom the vaccine site also contains peptide antigen. Our study differs from the murine model in that we observe T cell recruitment to the site injected with IFA alone. This may reflect that our examination takes place after repeated vaccination in the same site rather than observation after just one vaccine in the animal model. In previous immunohistochemical analysis of vaccine sites, we have demonstrated that single injections with adjuvant alone induce inflammatory dermal infiltrates which are transient and disorganized compared to those induced by repeated vaccination [10]. Though T cells in the VSME are clearly activated, evidence from the present study suggests that they are dysfunctional in their cytokine and proliferative responses to antigen, raising concerns about their ability to survive. In melanoma patients receiving vaccines in IFA, accumulation and persistent retention of T_{EM} with subsequent depletion of these potential effectors at the vaccine site may limit vaccine-induced tumor control.

We have previously reported that both $CD4^+$ and $CD8^+$ cells in the VSME induced with IFA are actively dividing, as manifest by Ki67 staining, and that T cells and mature DC are closely associated in the vaccine sites [10], raising the possibility of *in situ* priming in the VSME, though such priming may be dysfunctional. To the extent that peptide may also bind to other cells (*e.g.* fibroblasts), *in situ* priming may be ineffective or even toleragenic [16]. On the other hand, when activated T cells reactive to peptides in the vaccine are evident in VSME without peptide, it is likely that they have been recruited to the site after activation. Ongoing recruitment of $CD4^+$ and $CD8^+$ T cells to all vaccine sites containing IFA may be mediated in part by chemokines attracting the high proportion of CXCR3⁺ cells observed in the VSME compared to blood (Fig. 4). However, CLA is not consistently increased despite the skin location of the vaccines.

Even in VSME containing peptide, well over 95% of $CD8^+$ T cells in the VSME are tetramer^{neg}, indicating that the IFA-containing VSME appears to recruit and to stimulate T cells reactive to antigens other than those in the vaccine. The identity of those targets is not known, but we can hypothesize potential explanations: i) recruitment of circulating T cells

by cytokine-activated endothelium in the VSME, ii) decreased skin barrier function due to inflammation, with sensitization to environmental haptens and/or protein antigens in contact with the skin surface, and iii) reactivity to normal host skin antigens or melanocytic antigens due to injection of adjuvant into the skin.

T cell recruitment appears to lead to long-term retention, as substantial T cell aggregates in the VSME persist 6 weeks after the final vaccination [6]. Retention integrins provide a likely mechanism for the observed T cell sequestration within the VSME, as both E7 and 11 are significantly higher in sites where peptide antigen is present, with the most elevated expression in tetramer^{pos} T cells in group 2 (Fig. 5). E7 (CD103) binds E-cadherin on epithelial cells, and triggers CCR5 mediated recruitment and retention of T cells [17]. 11 (VLA-1) binds type IV collagen, and is critical for the development and maintenance of memory CD8⁺ T cells in peripheral tissues [18]. The significant elevation of E7 in group 2 vaccine sites over group 1 is likely related to the presence of antigen, with E7 upregulation dependent upon T cell receptor engagement with cognate antigen [19]. Systemic antitumor immunity may be compromised by recruitment and retention of T cells to the VSME, limiting circulation and homing to tumor.

Despite evident activation (CD69 positivity) of CD8⁺ T cells in the VSME and increased antigen-specific cells in the group 2 VSME, lymphocytes retained in the VSME are strikingly dysfunctional (Fig. 3). Consistent with previous murine model findings after similar vaccination with short peptides in IFA [11], T cells in our human study appear refractory to correction with IL-2 and antigen stimulation, suggesting that activated CD8⁺ T cells within the VSME are in a refractory or exhausted state.

Vaccines containing IFA can be highly effective inducers of antibody responses; however, IFA may not be an optimal adjuvant for induction of T cell responses to peptides. Though sample size in these pilot data precludes definitive conclusions regarding the role of antigen in dysfunction of lymphoid aggregates, the study provides evidence that vaccine sites with IFA recruit and retain activated, dysfunctional CD8⁺ T cells, predominantly of effector memory phenotype. Selective retention of antigen-specific CD8⁺ T cells within the VSME is suggested by increased tetramer^{pos} cells in the VSME of group 2 and high proportions of cells expression retention integrins. This may point to a significant mechanism underlying transient immune responses and low clinical response rates to peptide vaccines seen in the melanoma population to date. The same mechanism may interfere with combinations of T cell directed therapies (e.g. vaccines with adoptive T cell therapy, IL-2, or checkpoint blockade). This challenge may well be overcome by use of newer adjuvants and/or different vaccine formulations that avoid chronic inflammation in the VSME.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We greatly appreciate the work of Patrice Neese, Carmel Nail, and Priscilla Merrill in care of the patients on this trial, and Cheryl F. Murphy, Nadejda V. Galeassi, Kelly Smith and Elizabeth Coleman in immune analyses and data management. Funding support was provided by the National Institutes of Health Research Training Grant T32HL007849 (PI- Irving Kron) to EPS and the University of Virginia Rebecca Clay Harris Memorial Fellowship to SMS. Additional funding for this study was provided by the University of Virginia Cancer Center Support Grant (NIH/NCI P30 CA44579, Biorepository and Tissue Research Facility) and the University of Virginia General Clinical Research Center (NIH M01 RR00847). Peptides used in this vaccine were prepared with philanthropic support from the Commonwealth Foundation for Cancer Research and Alice and Bill Goodwin. Additional philanthropic support was provided by the James and Rebecca Craig Foundation, George S. Suddock, Richard and Sherry Sharp, and the Patients and Friends Research Funds of the University of Virginia Cancer Center. Montanide

ISA-51 (produced by Seppic, Inc.) was used in the vaccines of this trial, but paid for by the University of Virginia. No corporate funding support was provided for this study.

Abbreviations

CLA	cutaneous leukocyte antigen
HEV	high endothelial venule
IFA	incomplete Freund's adjuvant
PBMC	peripheral blood mononuclear cell
T_{CM}	central memory T cell (CD45RA ^{neg} /CCR7 ⁺)
T_{EM}	effector memory T cell (CD45RA ^{neg} /CCR7 ^{neg})
T_{EMRA}	CD45RA ^{pos} effector memory T cell (CD45RA ^{neg} /CCR7 ^{neg})
TLO	tertiary lymphoid organ
T_{naive}	naïve T cell (CD45RA ⁺ /CCR7 ⁺)
VSME	vaccine site microenvironment

References

1. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N Engl J Med*. 2011; 364(22):2119–2127.10.1056/NEJMoa1012863 [PubMed: 21631324]
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. *Nat Med*. 2004; 10(9):909–915.10.1038/nm1100 [PubMed: 15340416]
3. Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? *Cancer journal*. 2011; 17(5):343–350.10.1097/PPO.0b013e318233e5b2
4. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. *Clin Cancer Res*. 2007; 13(21):6386–6395.10.1158/1078-0432.CCR-07-0486 [PubMed: 17975151]
5. Freund J, Thomson KJ. A Simple, Rapid Technic of Preparing Water-in-Oil Emulsions of Penicillin, Drugs and Biologics. *Science*. 1945; 101(2627):468–469.10.1126/science.101.2627.468-a [PubMed: 17799002]
6. Schaefer JT, Patterson JW, Deacon DH, Smolkin ME, Petroni GR, Jackson EM, Slingluff CL Jr. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. *J Transl Med*. 2010; 8:79.10.1186/1479-5876-8-79 [PubMed: 20727190]
7. Lang A, Nikolich-Zugich J. Development and migration of protective CD8+ T cells into the nervous system following ocular herpes simplex virus-1 infection. *Journal of immunology*. 2005; 174 (5): 2919–2925.
8. Shomer NH, Fox JG, Juedes AE, Ruddle NH. Helicobacter-induced chronic active lymphoid aggregates have characteristics of tertiary lymphoid tissue. *Infection and Immunity*. 2003; 71(6): 3572–3577.10.1128/iai.71.6.3572-3577.2003 [PubMed: 12761142]
9. Weninger W, Carlsen HS, Goodarzi M, Moazed F, Crowley MA, Baekkevold ES, Cavanagh LL, von Andrian UH. Naïve T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. *Journal of immunology*. 2003; 170 (9):4638–4648.

10. Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB 2nd, Molhoek KR, Deacon DH, Patterson JW, Slingluff CL Jr. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. *Journal of immunotherapy*. 2012; 35(1):78–88.10.1097/CJI.0b013e31823731a4 [PubMed: 22130163]
11. Hailemichael Y, Dai Z, Jaffarad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Schluns KS, Davis RE, Hwu P, Overwijk WW. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. *Nat Med*. 2013; 19(4):465–472.10.1038/nm.3105 [PubMed: 23455713]
12. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multi-peptide melanoma vaccine. *J Clin Oncol*. 2011; 29(21):2924–2932.10.1200/JCO.2010.33.8053 [PubMed: 21690475]
13. Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multi-peptide melanoma vaccine: outcome of a multicenter randomized trial. *Clin Cancer Res*. 2009; 15(22):7036–7044.10.1158/1078-0432.CCR-09-1544 [PubMed: 19903780]
14. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu Rev Immunol*. 2004; 22:745–763.10.1146/annurev.immunol.22.012703.104702 [PubMed: 15032595]
15. Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. *International journal of cancer Journal international du cancer*. 1999; 83 (3):326–334. [PubMed: 10495424]
16. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. *Journal of immunology*. 2007; 179 (8):5033–5040.
17. Le Floc'h A, Jalil A, Franciszkiewicz K, Validire P, Vergnon I, Mami-Chouaib F. Minimal engagement of CD103 on cytotoxic T lymphocytes with an E-cadherin-Fc molecule triggers lytic granule polarization via a phospholipase Cgamma-dependent pathway. *Cancer Res*. 2011; 71(2): 328–338.10.1158/0008-5472.CAN-10-2457 [PubMed: 21224355]
18. Chapman TJ, Topham DJ. Identification of a unique population of tissue-memory CD4+ T cells in the airways after influenza infection that is dependent on the integrin VLA-1. *Journal of immunology*. 2010; 184(7):3841–3849.10.4049/jimmunol.0902281
19. Franciszkiewicz K, Le Floc'h A, Jalil A, Vigant F, Robert T, Vergnon I, Mackiewicz A, Benihoud K, Validire P, Chouaib S, Combadiere C, Mami-Chouaib F. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. *Cancer Res*. 2009; 69(15):6249–6255.10.1158/0008-5472.CAN-08-3571 [PubMed: 19638592]

Fig. 1. Mel48: A multi-peptide vaccine in melanoma patients with evaluation of the injection site microenvironment
Patients with resected AJCC stage IIB–IV melanoma underwent cutaneous vaccination with 12-melanoma peptide vaccine and tetanus helper peptide in incomplete Freund’s adjuvant (IFA). At a replicate vaccine site, Group 1 received IFA alone, Group 2 received full vaccination. Replicate vaccine sites were biopsied and peripheral blood collected as shown.

Fig. 2. Vaccine sites are depleted of naïve and enriched for effector memory CD8⁺ T cells compared to peripheral blood

Phenotypes of CD8⁺ T cells (T_{CD8}) were determined by multi-parameter flow cytometry staining with CCR7 and CD45RA. Cells were sorted by their ability to bind to tetramers relevant to the HLA type of the patient. Gating was performed on live, singlet, CD8⁺/CD4^{neg}/CD14^{neg}/CD19^{neg}, then tetramer^{pos} or tetramer^{neg} lymphocyte populations. The figure depicts percentages of CD8⁺ T cells staining with naïve (Naïve, CCR7⁺/CD45RA⁺) and effector memory (EM, CCR7^{neg}/CD45RA^{neg}) phenotypes. **a) T_{naïve} of tetramer^{neg} cells.** Values from vaccine site and/or peripheral blood at each time point are shown for each individual patient with a unique Subject ID. **b) T_{naïve} of tetramer^{pos} cells.** **c) T_{EM} of tetramer^{neg} cells.** **d) T_{EM} of tetramer^{pos} cells.**

Fig. 3. Marked activation, antigen specificity and cellular dysfunction in vaccine sites CD69 expression and staining with MHC-peptide tetramers in live, singlet, CD8⁺/CD4^{neg}/CD14^{neg}/CD19^{neg} lymphocyte populations were evaluated by multi-parameter flow cytometry. Functionality was assessed by IFN- γ response to vaccine peptides in direct ELISpot assay. **CD69 Expression.** **a)** Upper (group 1C) and lower (group 2C) panels display representative flow cytometry from the VSME and time-matched PBMC for individual patients. **b)** Percentages of CD8⁺ T cell populations staining positive for CD69 are shown for individual patient samples. **Tetramer staining.** Cells were sorted by their ability to bind MHC-peptide tetramers relevant to the HLA type of the patient. **c)** Upper (group 1C) and lower (group 2C) panels display representative flow cytometry from the VSME and time-matched PBMC for representative patients. Total numbers of cells evaluated per assay from the VSME were lower than in PBMC. **d)** **Tetramer^{pos} proportion of CD8⁺ T cell populations** for individual patients. **e)** **Ratio of ELISpot reactivity to tetramer.** The number of cells producing IFN- γ in response to vaccine peptides was compared to the number of tetramer positive cells per 10⁵ CD8⁺ T cells at each time point. Ratios of IFN- γ to tetramer^{pos} cells are depicted for individual patients.

Fig. 4. In vaccine sites, chemokine receptor CXCR3 expression is elevated

Live, singlet, CD14^{neg}/CD19^{neg} cells were identified and gated on CD4⁺, CD8⁺/Tetramer^{pos} or CD8⁺/Tetramer^{neg} populations. T_{CD8} = CD8⁺ T cells. T_{CD8} = CD8⁺ T cells. T_{CD4} = CD4⁺ T cells. **CXCR3 expression among a) tetramer^{neg} and b) tetramer^{pos} T_{CD8} and c) T_{CD4} are shown for individual patients. d) CXCR3 populations in a representative group 2C patient.** Each grey histogram is a negative control (FMO-CXCR3).

Fig. 5. Retention integrin expression is elevated in vaccine sites

Gating was performed on live, singlet, CD8⁺/CD4^{neg}/CD14^{neg}/CD19^{neg}, then tetramer^{pos} or tetramer^{neg} lymphocyte populations. T_{CD8} = CD8⁺ T cells. **a) Epithelial retention integrin**

E 7 among tetramer^{neg} cells. Percentages of tetramer^{neg} T_{CD8} populations staining positive for E 7 are shown for individual patients. **b) E 7 among tetramer^{neg} cells.. c) Collagen retention integrin 1 1 among tetramer^{neg} cells.** Percentages of tetramer^{neg} T_{CD8} populations staining positive for 1 1 are shown for individual patients. **d) Collagen retention integrin 1 1 among tetramer^{pos} cells** e) E 7 and 1 1 staining among tetramer^{neg} cells and f) tetramer^{pos} cells. Panels display representative flow cytometry from T_{CD8} from vaccine site biopsies and time-matched PBMC for a representative group 2C patient.

Table 1
Patient Demographics and Clinical Characteristics

This paper is based on a presentation given at the Tenth Annual Meeting of the Association for Cancer Immunotherapy (CIMT), held in Mainz, Germany, 23rd–25th May, 2012. Volume 62, Issue 5, May 2013 of *Cancer Immunology, Immunotherapy* includes a series of Focussed Research Reviews and meeting report from that conference.

Characteristics	group 1 (n= 23)		group 2 (n= 22)	
	No.	%	No.	%
Gender				
Male	16	70%	17	77%
Stage at enrollment				
IIB	3	13%	0	0%
IIC	1	4%	0	0%
IIIA	2	9%	3	14%
IIIB	8	35%	8	36%
IIIC	4	17%	9	41%
IV	5	22%	2	9%
ECOG PS ^a				
0	22	96%	20	91%
1	1	4%	2	9%
Median Age, years	56		53	
HLA-expression ^{b,c}				
HLA-A1	12	52%	10	45%
HLA-A2	8	35%	9	41%
HLA-A3	13	57%	9	41%
HLA-A11	2	9%	3	14%

^aECOG PS = Eastern Cooperative Oncology group performance status

^bHLA= Human leukocyte antigen

^cMany patients express more than 1 HLA type.